Johnson & Johnsonchalks up its recent oncology successes to increased R&D investment and a comprehensive, focused oncology strategy in particular disease areas – with hematological malignancies as a top target.
The company had a history in oncology with products like Doxil (doxorubicin) and Procrit (epoetin alfa) and the proteasome inhibitor...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
